Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

BioMark Diagnostics Inc

Healthcare US BMKDF

0.3917USD
-0.0061(1.53%)

Last update at 2026-06-23T18:13:00Z

Day Range

0.390.39
LowHigh

52 Week Range

0.170.46
LowHigh

Fundamentals

  • Previous Close 0.40
  • Market Cap45.96M
  • Volume250
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.95296M
  • Revenue TTM0.09M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.09M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -1.92728M -1.42738M -1.84223M -1.45390M -1.09419M
Minority interest - - - - -
Net income -1.92728M -1.42738M -1.84223M -1.45390M -1.09419M
Selling general administrative 1.00M 0.72M 1.15M 0.86M 0.96M
Selling and marketing expenses - 0.20M - - -
Gross profit - 0.16M 0.15M 0.04M -
Reconciled depreciation 0.40M 0.39M 0.39M 0.18M 0.01M
Ebit - -1.31222M -1.73200M -1.40311M -1.08258M
Ebitda - -0.91905M -1.34580M -1.22348M -1.06890M
Depreciation and amortization - 0.39M 0.39M 0.18M 0.01M
Non operating income net other - - - - -
Operating income -1.90814M -1.31568M -1.73200M -1.40311M -1.08258M
Other operating expenses - 1.48M 1.89M 1.45M 1.08M
Interest expense 0.06M 0.12M 0.11M 0.05M 0.00414M
Tax provision - - - - -
Interest income 0.00152M 0.00386M 0.00008M 0.00000M 0.00006M
Net interest income -0.06002M -0.11131M -0.11015M -0.04968M -0.00408M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.19349M - 0.05M 0.00414M
Total revenue 0.15M 0.16M 0.15M 0.04M 0.00000M
Total operating expenses 2.06M 1.48M 1.89M 1.45M 1.08M
Cost of revenue - 0.39M - - -
Total other income expense net 0.04M -0.11171M -0.11023M -0.00111M -0.00747M
Discontinued operations - - - - -
Net income from continuing ops -1.92728M -1.42738M -1.84223M -1.45390M -1.09419M
Net income applicable to common shares - - - -1.45390M -1.09419M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 3.13M 1.09M 0.73M 1.47M 0.95M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.00000M - - -
Total liab 1.39M 1.70M 1.88M 2.11M 1.03M
Total stockholder equity 1.74M -0.60961M -1.14958M -0.63569M -0.07909M
Deferred long term liab - - - - -
Other current liab - 0.00834M 1.65M 1.83M 0.89M
Common stock - 10.14M 8.24M 7.12M 6.88M
Capital stock 13.78M 10.14M 8.24M 7.12M 6.88M
Retained earnings -15.77309M -13.45043M -11.97827M -10.11793M -8.59061M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 2.48M 0.16M 0.07M 0.38M 0.88M
Cash and equivalents - - - - -
Total current liabilities 1.23M 1.24M 1.66M 1.50M 0.92M
Current deferred revenue - 0.00834M 0.01M 0.01M -
Net debt - 0.65M 0.75M 0.67M -0.75835M
Short term debt - 1.09M 0.61M 0.44M 0.00971M
Short long term debt - - 0.33M 0.14M -
Short long term debt total - 0.81M 0.82M 1.05M 0.12M
Other stockholder equity - 2.70M 2.59M 2.36M 1.64M
Property plant equipment - - - 0.97M 0.03M
Total current assets 2.64M 0.20M 0.13M 0.50M 0.92M
Long term investments 0.00320M 0.00320M 0.00320M 0.00320M 0.00320M
Net tangible assets - - - -0.63569M -0.07909M
Short term investments - - - - -
Net receivables 0.16M 0.04M 0.03M 0.08M 0.03M
Long term debt - - - 0.10M 0.09M
Inventory - - - - -
Accounts payable 0.27M 0.14M 0.22M 0.13M 0.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.35M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.03M 0.01M - -
Deferred long term asset charges - - - - -
Non current assets total 0.49M 0.89M 0.61M 0.97M 0.03M
Capital lease obligations 0.45M 0.81M 0.50M 0.81M 0.03M
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -0.00353M -0.00439M -0.00530M -0.05920M -0.00320M
Change to liabilities - - - 0.11M -0.08206M
Total cashflows from investing activities - - - -0.05920M -0.00320M
Net borrowings -0.41303M -0.73264M - -0.12914M 0.02M
Total cash from financing activities 3.42M 1.07M 0.61M 0.77M 0.72M
Change to operating activities - - - -0.01599M -0.01817M
Net income -1.92728M -1.42738M -1.84223M -1.45390M -1.09419M
Change in cash 2.33M 0.08M -0.31067M -0.49497M 0.27M
Begin period cash flow 0.16M 0.07M 0.38M 0.88M 0.61M
End period cash flow 2.48M 0.16M 0.07M 0.38M 0.88M
Total cash from operating activities -1.09313M -0.98252M -0.91442M -1.20393M -0.45555M
Issuance of capital stock 3.61M 1.54M 0.96M - -
Depreciation 0.40M 0.39M 0.39M 0.18M 0.01M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - -0.00865M - -0.05496M -0.01105M
Sale purchase of stock - - - - -
Other cashflows from financing activities - -0.06296M 0.03M 1.08M 0.74M
Change to netincome - - - 0.03M 0.38M
Capital expenditures 0.00353M 0.00439M 0.00530M 0.06M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.00498M -0.08645M 0.14M 0.04M 0.24M
Stock based compensation 0.37M 0.08M 0.33M 0.00000M 0.40M
Other non cash items 0.06M 0.06M 0.07M 0.03M -0.01101M
Free cash flow -1.09666M -0.98691M -0.91972M -1.26313M -0.45555M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMKDF
BioMark Diagnostics Inc		 -0.0061 1.53% 0.39 - - 500.80 119.36 657.92 -8.8335
TMO
Thermo Fisher Scientific Inc		 5.34 1.15% 469.35 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 0.78 0.44% 178.97 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 0.18 0.14% 126.67 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -4.42 0.81% 541.31 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

BioMark Diagnostics Inc

3851 Shell Road, Richmond, BC, Canada, V6X 2W2

Key Executives

Name Title Year Born
Mr. Rashid Ahmed Maula Bux B.Sc., MBA Founder, CEO, Pres & Director NA
Ms. Guoyu Huang MBA Chief Financial Officer NA
Mr. Brian Kai-Ming Cheng B.Sc., M.Sc, M.Sc. Chief Technical Officer & Independent Director NA
Dr. Jeff Haince Ph.D. GM & Chief Scientific Officer NA
Neal Kaplan Chief Financial Officer of US NA
Dr. Daniel Sitar Principal Scientific Advisor NA
Mr. Rashid Ahmed Maula Bux B.Sc., MBA Founder, CEO, President & Director NA
Mr. Brian Kai-Ming Cheng B.Sc., M.Sc. Chief Technical Officer & Independent Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.